Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with overactive bladder who completed a previous darifenacin short-term trial.~* Patients capable of independent toileting and able of independently completing the patient diary.~Exclusion Criteria:~* Patients in whom the use of anticholinergic drugs was contraindicated~* Evidence of severe liver disease~* Patients with other clinically significant urinary or gynecological conditions~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Darifenacin

Based on this trial design, predict the completion outcome and termination type (if applicable).